AbbVie pulls out of one ENHANZE collaboration program

21 November 2016
2019_biotech_test_vial_discovery_big

US pharma major AbbVie (NYSE: ABBV) has discontinued a development program using the ENHANZE platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a Phase I study in which the target results were not achieved.

Partner USA-based Halozyme Therapeutics (Nasdaq: HALO) and AbbVie will continue to work collaboratively to identify additional targets for co-development under their 2015 global collaboration and licensing agreement. TNF-alpha was the first nominated target of nine included as part of the agreement. Halozyme’s shares dipped 3.18% to $12.41 in morning trading, while AbbVie was barely changed.

In June 2015, Halozyme entered into a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform, potentially valued at $1.19 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology